Billion dollar orphans

Billion dollar orphans View Gallery

They’re the drugs that combat the rarest of diseases. But they’re so specialised that their price tags are increasingly putting them out of reach. How much longer will Irish patients continue to miss out on such medicines?

There is a widespread perception that new drugs will only be made available to those patients who shout the loudest. The process lacks transparency. The industry’s morals are questionable. As the medicines watchdog predicts an avalanche of expensive orphan drugs, what does the future hold for those with a rare disease?

Please Subscribe or Log in to continue reading

Subscribe Login

Independent journalism every day

With digital access you can read The Business Post whenever, wherever, and however you want.

  • Unlimited access to all sections of The Business Post on desktop, tablet and mobile.
  • Breaking news, comment and analysis from the best Business Post writers seven days a week.
  • Live blogs of major news events
  • Videos and podcasts from some of the industry's most respected journalists such as Tom Lyons, Susan Mitchell and Ian Guider
  • Access to The Business Post's extensive archive​

Related Articles

More from The Business Post